New Analysis Suggests Focal Inflammatory Lesions May Not Signal Treatment Failure
[City, Country] – [Date] – In a significant development for multiple sclerosis (MS) management, Sanofi has presented compelling data suggesting that the emergence of new focal inflammatory lesions, a long-standing indicator of treatment inadequacy, may not necessarily signify treatment failure for its investigational drug, Cenrifki (tolebrutinib). This groundbreaking analysis, presented at the 12th Congress of the European Academy of Neurology (EAN) 2026, challenges conventional interpretations of MRI activity in MS patients and offers a more nuanced understanding of how to evaluate the efficacy of therapies targeting disease progression.
Previously, the appearance of new Gadolinium-enhancing (Gd+) T1 lesions or new/enlarging T2 lesions on Magnetic Resonance Imaging (MRI) has been a critical trigger for clinicians to reassess treatment strategies, often leading to therapy modification or escalation, particularly in relapsing forms of MS. This approach is rooted in the understanding that such lesions represent active inflammation and a potential lack of response to the prescribed disease-modifying therapy (DMT). However, Sanofi’s post hoc analysis of data from the pivotal Phase III HERCULES trial and the GEMINI program indicates that Cenrifki may continue to provide a significant disability benefit even in the presence of these inflammatory markers.
Key Findings: Rethinking MRI Activity in MS Treatment
The core of Sanofi’s revelation lies in its post hoc analysis, which examined the relationship between new focal inflammatory lesions and the risk of confirmed disability accumulation (CDA) in patients treated with Cenrifki. The findings suggest a paradigm shift in how MRI activity should be interpreted in the context of specific DMTs like Cenrifki, which are designed to address chronic inflammation and prevent long-term disability.
- Disability Benefit Persists Despite Lesion Activity: The analysis revealed that Cenrifki effectively reduced the risk of CDA by 31% relative to placebo in patients with non-relapsing secondary progressive MS (nrSPMS) and by 29% relative to teriflunomide in patients with relapsing MS (RMS). Crucially, this reduction in disability risk was observed irrespective of whether patients developed new focal inflammatory lesions during the trial. This means that Cenrifki demonstrated a significant benefit in slowing disability progression for both patients who remained lesion-free and those who developed new Gd+ T1 lesions or new/enlarging T2 lesions.
- Targeting Chronic Inflammation: This data strongly supports Cenrifki’s proposed mechanism of action, which focuses on targeting chronic inflammation that drives disability progression, rather than solely acute inflammatory relapses. The drug’s ability to mitigate disability even when new lesions appear suggests a sustained impact on the underlying pathological processes contributing to irreversible neurological damage.
- Challenging Traditional Indicators of Treatment Failure: The analysis directly challenges the long-held clinical practice of automatically interpreting new focal inflammatory lesions as a sign of treatment failure. Sanofi’s evidence suggests that for Cenrifki, the development of these lesions should not be considered a definitive indicator that the drug is not working.
Chronology of Data Presentation and Approval
The presentation of this significant analysis at the EAN Congress 2026 is a pivotal moment, occurring shortly after a major regulatory milestone for Cenrifki.
- June 27, 2026: Sanofi presented the post hoc analysis data during the poster presentation session titled "MS and Related Disorders 1" at the 12th Congress of the European Academy of Neurology (EAN) 2026, held in [City, Country – if known, otherwise omit or use placeholder]. This provided a platform for global neurologists and researchers to engage with the novel findings.
- June 23, 2026: Just four days prior to the EAN presentation, Cenrifki received approval in the European Union (EU) for the treatment of nrSPMS in patients who have not experienced relapses in the preceding two years. This approval marks a significant achievement, positioning Cenrifki as the first-in-class product specifically designed to target disability accumulation in this patient population.
- Upcoming EU Launch: With the EU launch of Cenrifki imminent, Sanofi is strategically positioned to introduce a new therapeutic approach that diverges from the traditional reliance on new focal inflammatory lesions as a sole indicator of treatment failure for drugs aimed at halting MS disability progression.
Supporting Data: The HERCULES and GEMINI Trials
The insights presented at the EAN Congress are derived from robust clinical trial data. The Phase III HERCULES trial (NCT04411641) and the GEMINI program, encompassing trials NCT04410978 and NCT04410991, were instrumental in evaluating Cenrifki’s efficacy and safety.
- HERCULES Trial: This trial focused on patients with non-relapsing secondary progressive MS (nrSPMS). The trial’s primary objective was to assess Cenrifki’s ability to reduce the risk of confirmed disability accumulation.
- GEMINI Programme: This programme investigated Cenrifki’s efficacy in patients with relapsing forms of MS (RMS). The trials were designed to evaluate the drug’s impact on relapses and disability progression in this diverse patient group.
The post hoc analysis meticulously dissected the MRI data from these trials, correlating the presence or absence of new focal inflammatory lesions with the observed clinical outcomes in terms of disability progression. The consistent demonstration of a disability benefit across both lesion-positive and lesion-negative patient subgroups underscores the robustness of these findings.
Official Responses and Expert Commentary
While direct quotes from Sanofi spokespersons at the time of the article’s original publication may be limited, the implications of this research are profound and are likely to be met with keen interest and discussion within the neurology community.
Sanofi’s Stance: The company’s proactive presentation of this analysis, particularly in conjunction with the EU approval, signals a strategic intent to educate clinicians about a new paradigm for evaluating treatment response. Sanofi appears to be advocating for a more holistic approach that acknowledges the multifaceted nature of MS pathology and the diverse mechanisms by which DMTs exert their effects.
Potential Expert Reactions: Neurologists and MS specialists are expected to engage with these findings critically. While the traditional interpretation of MRI lesions is deeply ingrained, evidence suggesting that a drug can decouple lesion formation from disability progression is compelling. This could lead to:
- Revised Clinical Practice Guidelines: Over time, these findings might influence the development of updated clinical practice guidelines for MS management, potentially altering the criteria for treatment escalation.
- Focus on Broader Biomarkers: The analysis implicitly highlights the limitations of relying on a single imaging marker. This could accelerate research and adoption of a broader suite of biomarkers for monitoring MS progression.
- Patient-Centric Care: A more nuanced understanding of treatment efficacy could lead to more personalized treatment strategies, focusing on individual patient responses and long-term outcomes rather than solely on transient MRI activity.
Implications for Multiple Sclerosis Management
The implications of Sanofi’s findings extend far beyond the specific context of Cenrifki and are poised to reshape the landscape of multiple sclerosis treatment evaluation.
- Shifting the Focus to Disability Progression: The core message is a crucial one: for certain therapies, particularly those targeting chronic inflammation and disability accumulation, the primary measure of success should be the slowing or halting of irreversible neurological damage, not solely the absence of acute inflammatory lesions. This aligns with the growing understanding that MS is a progressive disease where sustained disability accumulation poses the greatest long-term threat to patients’ quality of life.
- Limitations of Standalone MRI Markers: The analysis strongly suggests that new focal inflammatory lesions, while indicative of active inflammation, may not be the most accurate standalone predictor of whether a drug targeting progression is achieving its main clinical benefit. This calls into question the universal applicability of this metric across all MS DMTs and encourages a more targeted interpretation based on a drug’s specific mechanism of action.
- The Need for Comprehensive Monitoring: To overcome the limitations of relying on a single marker, the research points towards the necessity of a multi-modal approach to monitoring disease progression. This could include:
- Advanced Imaging Biomarkers: Beyond Gd+ T1 and T2 lesions, other MRI techniques like paramagnetic rim lesions (PRLs) and slowly expanding lesions (SELs) may offer more sensitive indicators of chronic, smoldering inflammation and neurodegeneration. Accelerated brain atrophy measurement is also a critical indicator of long-term disease progression.
- Clinical Assessments: Continued reliance on clinical evaluations of disability, including standardized neurological examinations and patient-reported outcomes, remains paramount.
- Biomarkers: Exploration and validation of blood and cerebrospinal fluid (CSF) biomarkers that reflect underlying disease processes and treatment response will be increasingly important.
- Empowering Clinicians and Patients: By providing evidence that new lesions don’t automatically equate to treatment failure, Sanofi’s research could empower clinicians to maintain effective therapies for longer, avoiding unnecessary treatment switches that can lead to treatment gaps and potential loss of efficacy. For patients, this offers reassurance that their treatment may still be working effectively even if their MRI shows some new activity.
- The Dawn of Targeted Therapies: The approval and emerging data on Cenrifki represent a significant step towards therapies that are specifically designed to combat the insidious progression of MS. As our understanding of MS pathology deepens, we can expect to see more drugs tailored to specific disease mechanisms, requiring equally sophisticated methods for evaluating their impact.
In conclusion, Sanofi’s post hoc analysis presented at the EAN Congress 2026 marks a significant advancement in the understanding and evaluation of multiple sclerosis treatments. By challenging the traditional interpretation of focal inflammatory lesions as a sole indicator of treatment failure for Cenrifki, the company is paving the way for a more nuanced, patient-centric approach to MS management, one that prioritizes long-term disability prevention and leverages a comprehensive suite of monitoring tools. This development holds the promise of optimizing treatment strategies and ultimately improving the lives of individuals living with this complex neurological condition.
About the Author
